Microplastics and Nanomaterials: Understanding Emerging Contaminants in Environmental Testing

🎤Matthew BolinoHow do the hidden carbohydrate structures on your favorite protein powders shape the gut microbiome? &nbsp;In this episode of Concentrating on Chromatography, Matthew Bolino, M.S., from the University of Nevada, Reno, breaks down his latest research on N‑glycans from common dietary proteins (whey, egg white, soy, and pea) and how their structural diversity influences microbial fermentation and short‑chain fatty acid production.Bolino explains what N‑glycans are, why they behave like fiber in the gut, and how his team isolates and characterizes them using ethanol washes, enzymatic release (PNGase F and gut‑derived endoglycosidases), and advanced MALDI‑TOF and HILIC‑QTOF workflows. &nbsp;He also discusses his 2025 work comparing synthetic versus bovine whey N‑glycomes and mapping N‑glycan profiles across dietary protein sources, revealing how glycan architecture can reshape community diversity in in vitro fecal fermentations.Geared toward undergraduate and early‑career analytical chemists, this conversation dives into practical mass spec trade‑offs (MALDI vs QTOF vs LC/GC), real‑world troubleshooting in glycomics labs, and how microbiome‑targeted therapeutics and “symbiotic” designs may emerge from pairing specific microbes with preferred glycan structures. &nbsp;Bolino closes with career advice on building biomolecular analysis skills, understanding instrumentation fundamentals, and entering the rapidly growing field of glycomics and microbiome research.<h3>Video Transcription</h3><h4>Introduction</h4>Glycomics has emerged as a rapidly developing field within biomolecular science, expanding our understanding of post-translational modifications beyond well-known processes such as phosphorylation. Among these modifications, protein glycosylation—the covalent attachment of carbohydrate structures to proteins—plays a critical role in biological function, molecular recognition, and cellular communication.This discussion focuses on N-glycans, a class of structurally complex carbohydrates linked to proteins, and their occurrence in common dietary protein sources such as whey, egg white, soy, and pea protein. Particular emphasis is placed on their structural diversity, analytical workflows, and emerging relevance in gut microbiome research.<h4>Fundamentals of N-Glycans</h4>N-glycans are oligosaccharide structures covalently attached to proteins via nitrogen atoms, typically at asparagine residues. They represent one of the two major classes of protein glycosylation, alongside O-glycans.These glycans are characterized by:<ul><li>High structural diversity, arising from variations in monosaccharide composition and linkage patterns</li><li>Large size, typically comprising 7–15 monosaccharide units</li><li>Complex branching architectures, leading to a vast number of possible configurations</li></ul>Common monosaccharide components include:<ul><li>Mannose</li><li>Galactose</li><li>N-acetylglucosamine</li><li>N-acetylgalactosamine</li><li>Sialic acids</li></ul>Unlike free carbohydrates present in foods (e.g., glucose, lactose), N-glycans are protein-bound, which significantly influences their biological behavior.<h4>Biological Function and Dietary Relevance</h4>N-glycans play multiple roles in biological systems, including:<ul><li>Modulation of protein stability</li><li>Regulation of protein trafficking and localization</li><li>Facilitation of cell–cell communication and immune recognition</li></ul>They are particularly abundant on membrane and surface proteins, where they contribute to molecular signaling processes.From a dietary perspective, N-glycans exhibit unique behavior. Due to their size and protein-bound nature, they are not readily digested in the upper gastrointestinal tract. Instead, they can reach the colon, where they may function analogously to dietary fiber, interacting with the gut microbiota.<h4>Research Motivation</h4>The investigation of N-glycans in dietary proteins was initially driven by interest in protein nutrition and supplementation, particularly in the context of muscle growth and protein quality. However, this focus expanded upon recognition of the importance of glycosylation in biological systems.The field of glycomics offers:<ul><li>Extensive structural variability, enabling diverse biological functions</li><li>Relevance in disease mechanisms, including cancer, where glycosylation patterns can influence immune evasion</li><li>Opportunities to explore diet–microbiome interactions</li></ul>This combination of nutritional, biochemical, and biomedical relevance makes N-glycan research particularly compelling.<h4>Experimental Workflow for N-Glycan Analysis</h4>The analysis of N-glycans requires a multi-step workflow due to their covalent attachment to proteins.<h5>1. Protein Purification</h5>Dietary protein samples often contain:<ul><li>Free sugars</li><li>Lipids</li><li>Other matrix components</li></ul>To isolate glycoproteins:<ul><li>Cold ethanol precipitation is used to remove free carbohydrates</li><li>Multiple washing steps ensure removal of residual sugars</li><li>A phenol–sulfuric acid assay is applied to confirm the absence of free sugars</li></ul><h5>2. Enzymatic Release of N-Glycans</h5>N-glycans are enzymatically cleaved from proteins using:<ul><li>PNGase F (Peptide-N-Glycosidase F)</li></ul>This enzyme:<ul><li>Specifically cleaves the glycan from the protein backbone</li><li>Preserves the intact glycan structure</li></ul>Alternative approaches using gut-derived enzymes are being explored to improve accessibility and yield.<h5>3. Glycan Purification and Labeling</h5>Following release:<ul><li>Glycans are purified from the protein matrix</li><li>Chemical labeling is performed (e.g., 2-AA or procainamide tagging)</li></ul>Labeling enhances:<ul><li>Detection sensitivity</li><li>Chromatographic behavior</li></ul><h5>4. Analytical Techniques</h5>Two primary analytical platforms are employed:<ul><li>MALDI-TOF MS<ul><li>High sensitivity</li><li>Broad structural coverage</li></ul></li><li>HILIC-LC-MS<ul><li>Improved reproducibility</li><li>Enhanced chromatographic separation</li></ul></li></ul>These approaches provide semi-quantitative data, where signal intensity reflects relative abundance rather than absolute concentration.<h4>Analytical Challenges</h4>Several challenges are associated with N-glycan analysis:<h5>Low Abundance</h5><ul><li>Dietary proteins typically contain only 1–2% glycan content by weight</li><li>This limits yield and complicates downstream applications</li></ul><h5>Sample Preparation Complexity</h5><ul><li>Extensive purification is required to eliminate free sugars</li><li>Contamination risks must be carefully managed</li></ul><h5>Instrumentation Trade-Offs</h5><ul><li>Different analytical platforms offer complementary advantages</li><li>No single technique provides complete structural and quantitative information</li></ul><h4>Differences Between Plant and Animal N-Glycans</h4>Comparative analysis reveals distinct differences in glycan composition:<h5>Plant-Derived Proteins (e.g., soy, pea)</h5><ul><li>Predominantly high-mannose structures</li><li>Lower monosaccharide diversity</li><li>Simpler glycan architectures</li></ul><h5>Animal-Derived Proteins (e.g., whey, egg white)</h5><ul><li>Greater structural complexity</li><li>Inclusion of diverse monosaccharides (e.g., sialic acids)</li><li>More elaborate branching patterns</li></ul>These differences have important implications for biological function and microbial interactions.<h4>Implications for Gut Microbiome Research</h4>N-glycans represent a potential class of prebiotic substrates that can influence gut microbiota composition and activity.Key findings suggest:<ul><li>Structural diversity of glycans affects microbial utilization patterns</li><li>More complex glycans may promote greater microbiome diversity</li><li>Specific glycan structures may selectively stimulate beneficial microbes</li></ul>This has led to growing interest in:<ul><li>Synbiotic strategies, combining microbes with preferred substrates</li><li>Tailored dietary interventions to enhance metabolic outputs, such as short-chain fatty acids</li></ul><h4>Methodological Considerations</h4>A critical insight from this work is the importance of understanding analytical trade-offs:<ul><li>MALDI-TOF MS provides broader detection of glycan structures</li><li>LC-MS approaches offer greater reproducibility</li></ul>No single technique is universally optimal; instead, method selection should be guided by the specific research question.<h4>Conclusion</h4>N-glycans in dietary proteins represent a complex and biologically significant class of biomolecules with implications spanning nutrition, microbiology, and disease research. Advances in analytical methodologies continue to improve our ability to characterize these structures, despite challenges related to low abundance and structural diversity.A deeper understanding of N-glycan composition and function may enable the development of targeted nutritional strategies and microbiome-based therapeutics, highlighting the growing importance of glycomics in modern life sciences.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

N‑Glycans, Whey Protein, and the Gut Microbiome: Mass Spec Insights with Matthew Bolino

<div><div><div>Our immune system is incredibly powerful: among other things, it can recognize and destroy cancer cells. But tumors can be just as effective at avoiding detection – they build “invisibility shields” to protect themselves from attack.</div></div><div>One breakthrough in cancer therapy has been immune checkpoint inhibitors (ICIs), drugs that reactivate immune T cells and help them fight tumors again. However, only about 20–50% of patients respond well to this treatment. Researchers are therefore seeking alternative therapeutic strategies. A small and well-known molecule called adenosine plays a key role in these efforts.When tumor cells are stressed or dying, they release ATP, which is normally a signal that something is wrong in the tissue. But in the tumor microenvironment, ATP gets rapidly broken down by two enzymes, CD39 and CD73. Released adenosine acts like a chemical “calm-down” signal, binds to immune cells (T cells, NK cells, and others), and tells them to slow down, reducing their ability to kill cancer cells. Targeting CD73 therefore represents a promising strategy for developing new cancer treatments.</div><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg" alt="IOCB Prague: Development of potent inhibitors to boost the immune system's ability to fight cancer" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg 245w," sizes="100vw" width="661" height="363">At IOCB Prague, interdisciplinary teams led by Jan Řezáč, Jan Konvalinka, and Michal Hocek used a newly developed high-throughput screening method to test over 5,000 compounds, identifying two ribonucleoside derivatives as promising CD73 inhibitors.The scientists then improved the compounds’ activity by carefully modifying the ribonucleoside scaffold with bulky (het)aryl groups. Further optimization improved the pharmacokinetic properties of these compounds, yielding inhibitors with low clearance, long half-life, high solubility, and strong selectivity over related enzymes such as CD39.In cellular experiments, the compounds reduced adenosine production in cancer cells, restored T cell activation, and showed no toxicity toward human fibroblasts. The most active compound showed a single-digit picomolar inhibition constant (Ki).These findings establish a strong foundation for further in vivo efficacy and combination studies, which will explore the therapeutic potential of this novel inhibitor class.<blockquote><h4>The Original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707">Potent Competitive Inhibitors of Ecto-5′-nucleotidase (CD73) based on 6-(Het)aryl-7-deazapurine Ribonucleoside 5′-O-Bisphosphonates</a></h4>Ugnė Šinkevičiu̅tė, Magdalena Šímová, Radek Staník, Lenka Poštová Slavětínská, Kristýna Blažková, Pavel Šácha, Martin Lepšík, Jan Řezáč, Jan Konvalinka, Tereza Ormsby, Michal Tichý, Michal HocekACS Pharmacol. Transl. Sci. 2026, 9, 1, 191–213<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707">https://pubs.acs.org/doi/10.1021/acsptsci.5c00707</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote><h4>Abstract</h4>CD73 generates immunosuppressive adenosine in the tumor microenvironment and is a promising target for cancer immunotherapy. We have designed and systematically studied diverse 2-substituted 7-deazapurine ribonucleoside 5′-O-bisphosphonates bearing a variety of (het)aryl groups at position 6 and discovered their highly potent and selective CD73 inhibition activity. The most active compounds (with single-digit picomolar Ki) contained bicyclic (het)aryl groups at position 6 in combination with chlorine at position 2. Further optimization of pharmacokinetic properties identified inhibitors with low clearance, long half-life, high solubility, and excellent selectivity over CD39 and NTPDase3. They effectively suppressed adenosine formation in MDA-MB-231 cells, rescued CD8+ T cell activation, and were nontoxic to human fibroblasts. Overall, their profile compares favorably with AB680, a CD73 inhibitor currently in phase I/II clinical trials.</div>

Development of potent inhibitors to boost the immune system's ability to fight cancer

Article

Video

Scientists

Environment

Scientific article

Interview

Science and research

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. 

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Separation Science

Merck

Agilent Technologies

Phenomenex

Thermo Fisher Scientific

SelectScience

Waters Corporation

Reversed-phased chromatography is both highly selective and versatile. It is no wonder that it is one of the most widely used methods for both small molecules and biomolecules. However, this wide applicability also makes this one of the most diverse methods. From the numerous stationary phases to pore sizes and mobile phases additives, it seems as though there are endless combinations to choose from. From this plethora of choices, how do you develop the best method for your biomolecule?
In this session, we discuss how to make the most of your reversed-phased analysis of biomolecules. From column selection to method conditions and mobile phases, we will discuss how you can optimize these factors for your biomolecule analysis. And, for when things don’t go according to plan, we will discuss how to troubleshoot your method when things go awry.
<blockquote>
Presenter: Melissa Goodlad (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Melissa Goodlad is an Application Engineer providing applications assistance and technical support for Agilent’s HPLC columns and consumables. Before joining Agilent, Melissa was completing her PhD in Physical Chemistry at UC Merced studying nanoparticle self-assemblies.
</blockquote>

Agilent Technologies: Reversed-Phase for Biomolecules: From Column Selection to Troubleshooting

Reversed-Phase for Biomolecules: From Column Selection to Troubleshooting

We will discuss how to make the most of your reversed-phased analysis of biomolecules.

RP for Biomolecules: Column Selection & Troubleshooting

Learn how to improve assay robustness and reduce the burden associated with migrating methods downstream in the analysis and monitoring of product quality attributes of biopharmaceuticals.
<blockquote>
Presenter: Pawel Bigos (Scientist, Waters Corporation)
</blockquote>
<blockquote>
Pawel is a Scientist at Waters Corporation in the QA/QC Biologics group. He joined Waters in 2022 and has primarily focused on biomolecule separations using Ion-Exchange (IEX) and Size Exclusion (SEC) Chromatography. Prior to Waters, he held positions at Frequency Therapeutics, Novartis, and Symbiotic Research. Pawel received his BS degree in chemistry from the University of South Florida.
</blockquote>

Waters Corporation: Advancing Technology for Better Medicine

Advancing Technology for Better Medicine

Learn how to improve assay robustness and reduce the burden associated with migrating methods downstream.

In modern pharmaceutical analysis, the utilization of Pharmacopeia regulated U/HPLC (ultra/high-performance liquid chromatography) methods has become a fundamental aspect of laboratory operations.
This webinar aims to explore the diverse strategies and techniques that can be employed to fully leverage the potential of U/HPLC method adaptation, thereby enhancing the effectiveness and efficiency of laboratory processes. The presentation delves into the principles of U/HPLC and highlights the significance of adhering to Pharmacopeia regulations for ensuring reliable and accurate analytical results. Furthermore, various approaches for method adaptation, such as modification of mobile phase composition, adjustment of column parameters, and optimization of detection conditions will be discussed, including the benefits and challenges associated with each adaptation strategy and insights into the factors influencing method transfer and development.
Additionally, the potential applications of U/HPLC method adaptation in pharmaceutical quality control, impurity profiling, and stability testing will be explored. By understanding the nuances and intricacies of U/HPLC method adaptation, laboratories can unlock new avenues for improving productivity, reducing costs, and enhancing the overall quality of pharmaceutical analysis.
By attending this presentation you will:
<ul>
<li>Learn about the principles and importance of U/HPLC method adaptation in pharmaceutical analysis and how improved methods can help to boost laboratory effectiveness and efficiency
</li>
<li>Gain insights into the significance of adhering to Pharmacopeia regulations for ensuring reliable and accurate analytical results
</li>
<li>Understand various strategies and techniques for adapting U/HPLC methods, such as modifying mobile phase composition, and adjusting column parameters
</li>
<li>Leverage the full potential of U/HPLC method adaptation leading to improved productivity and cost reduction in the laboratory
</li>
</ul>
Who should attend
<ul>
<li>Lab managers and technicians working with HPLC/UHPLC methods (R&amp;D, QC and method transfer).</li>
</ul>
<blockquote>
Presenter: 
</blockquote>
<blockquote>
Presenter: Petra Lewits (Global Product Manager for Analytical Chromatography, HPLC columns, Merck KGaA, Darmstadt, Germany)
</blockquote>
<blockquote>
Petra Lewits has worked with chromatography for 40 years. In 1986 she joined the pharmaceutical R&amp;D and QC department (Merck KGaA, Darmstadt, Germany) where she developed HPLC methods for R&amp;D and QC of pharmaceutical APIs and formulations as well as for diet convenience foods. Since 2002 she has been a Global Product Manager for Analytical Chromatography (HPLC). In 2014 she began focusing on thin-layer chromatography (TLC). Since April 2018 Petra has had global responsibility for analytical HPLC columns.
</blockquote>
<blockquote>
Presenter: Egidijus Machtejevas (Senior Technical Advisor, Analytical Chromatography Workflows, Merck KGaA, Darmstadt, Germany)
</blockquote>
<blockquote>
Egidijus Machtejevas joined the R&amp;D Department at Merck KGaA, Darmstadt, Germany in 2008. A year later he became marketing manager for North America, and in 2010–2018 Product Manager for chromatography. Currently he is a Senior Technical Advisor in the Analytical Chromatography Workflows group. Egidijus has twenty-five scientific papers and thirteen book chapters to his name, and his major focus areas include chromatography, multidimensional liquid chromatography, proteomics and mass spectrometry.
</blockquote>

Pixabay/Ri Butov: Leverage the full potential of Pharmacopeia regulated U/HPLC method adaptation to increase lab effectiveness

Leverage the full potential of Pharmacopeia regulated U/HPLC method adaptation to increase lab effectiveness

Explore the diverse strategies and techniques that can be employed to fully leverage the potential of U/HPLC method adaptation.

Leverage the full potential of Pharmacopeia

Join us for an informative webinar where we&#39;ll unveil our innovative in-house method for studying Extractables and Leachables (E&amp;L) substances in common medical and pharmaceutical-grade plastics.
We&#39;ll dive into the analysis of nylon, polyurethane, and PVC (epoxidized soybean oil) oligomers, showcasing our approach that leverages multiple advanced detectors to analyze a wide range of analytes with diverse chemical properties.
Our method incorporates an ingenious inverse gradient technique, fine-tuned with an in-line mixer and optimized gradient delay times. We&#39;ll demonstrate the application of a previously published calculation to determine analyte behavior, classifying them as non-volatiles or semi-volatiles using CAD (Charged Aerosol Detection).
By attending, you&#39;ll discover how our approach minimizes inter-analyte response factor variation, enhancing quantitative accuracy and reducing uncertainty in setting analytical evaluation thresholds. Ultimately, our method is designed to meet crucial requirements in E&amp;L studies, ensuring efficient and cost-effective protection against potentially harmful substances. Don&#39;t miss this opportunity to stay at the forefront of E&amp;L research.
Learning points:
<ul>
<li>determine which analytes behave as non-volatiles with CAD and can therefore be accurately quantified using surrogate standards
</li>
<li>improve quantification accuracy and reduce response factor variation using an inverse gradient
</li>
<li>use an in-line mixer to combine the analytical and inverse gradients and improve response uniformity
</li>
</ul>
Who should attend:
<ul>
<li>Laboratory managers and directors
</li>
<li>Technology leaders 
</li>
<li>Principal scientists 
</li>
<li>Laboratory analyst
</li>
</ul>
<blockquote>
Presenter: Katherine Lovejoy (Product Applications Specialist, Thermo Fisher Scientific)
</blockquote>
<blockquote>
Katherine Lovejoy, Ph.D. has been an application chemist focusing on charged aerosol detection at the Thermo Fisher Scientific HPLC factory site since 2016 and has a Ph.D. in inorganic chemistry from the Massachusetts Institute of Technology. She has experience as a chemist reviewer at the FDA and as a scientist at Los Alamos National Laboratory.
</blockquote>
<blockquote>
Presenter: Chris Tuczemskyi (Moderator, Product Marketing Manager, Thermo Fisher Scientific)
</blockquote>
<blockquote>
Chris Tuczemskyi is a chromatography specialist at Thermo Fisher Scientific, based in Cambridge, UK. After spending a number of years building up his experience with chromatography instruments in a water testing laboratory, he joined Thermo Fisher Scientific in 2014 as a chromatography service engineer for Unity Lab Services. Here he developed his passion for supporting customers using HPLC and in 2018 moved into the application specialist team. More recently, in 2022 he made the move to Product Marketing to help ensure we meet and exceed our customers expectation. In 2009, Chris graduated from the University of Essex in Biochemistry (Bsc Hons).
</blockquote>

Thermo Scientific: How HPLC-CAD Analysis Can Allow You to See Hidden Extractable Oligomers

How HPLC-CAD Analysis Can Allow You to See Hidden Extractable Oligomers

Innovative in-house method for studying Extractables and Leachables (E&L) substances in common medical and pharmaceutical-grade plastics.

How HPLC-CAD Analysis Can Allow You to See Hidden Oligomers

Join us for our 3-Part series to Meet our Experts and discuss topics including:
<ul>
<li>History of HPLC column technology over the last 50 years and how advancements have helped address current separation challenges.</li>
<li>Fundamentals of small molecule separations to enable you to develop methods more efficiently. </li>
<li>Solvent and column choices with UPLC to develop more environmentally friendly chromatography methods</li>
</ul>
<h3>PART 2: Fundamentals of HPLC Separations for Small Molecule Analyses</h3>
The advantages of HPLC in the separation and measurement of small molecule analyses leads us to consider how chromatography works and how the technology can be adapted to our needs. Understanding chromatographic terms such as resolution (Rs), alpha (a), retention factor (k), and efficiency (N) and the operating conditions which affect them is key in developing successful separations. In this presentation the components of a simple HPLC system will be described and their function highlighted. Special focus will be placed on the HPLC column and the range of particle technologies available. This basic understanding and knowledge of chromatographic fundamentals will provide a solid first step in developing separations for small molecules analyses.
<blockquote>
Presenter: Bonnie Alden (Principal Scientist, Research &amp; Development, Waters Corporation)
</blockquote>
<blockquote>
Bonnie Alden joined Waters Corporation in 1982 to work with Dr. Patrick McDonald to develop new Sep-Pak Cartridge SPE devices. During her career, she has been a member of teams that brought transformative chromatographic columns to market. These include Symmetry Columns which set the industry standard in reproducibility, 1st hybrid chromatographic packing of XTerra Columns, 2nd generation Ethylene Bridged Hybrid (BEH) and Charged Surface Hybrid (CSH) technologies, as well as the recent development of modern, mixed-mode stationary phases for challenging analyses, such as the retention and separation of polar acids. More than 35 years later, she is still an enthusiastic student of liquid chromatography and separation science. Bonnie is currently a principal scientist in the Small Molecule Portfolio Team where her research interests have focused on developing products to address the needs of scientists in the extensive field of small molecule drug development.
</blockquote>

Waters Corporation: Fundamentals of HPLC Separations for Small Molecule Analyses

Fundamentals of HPLC Separations for Small Molecule Analyses

Fundamentals of small molecule separations to enable you to develop methods more efficiently. 

Join us for our 3-Part series to Meet our Experts and discuss topics including:
<ul>
<li>History of HPLC column technology over the last 50 years and how advancements have helped address current separation challenges.
</li>
<li>Fundamentals of small molecule separations to enable you to develop methods more efficiently. 
</li>
<li>Solvent and column choices with UPLC to develop more environmentally friendly chromatography methods
</li>
</ul>
<h4>PART 3: Achieving Your Sustainability Goals with UPLC</h4>
Method development for reversed-phase high-performance liquid chromatography (HPLC) separations has traditionally been conducted using acetonitrile-water or methanol-water gradients. Acetonitrile is often preferred because of its ability to dissolve a wide range of solutes, its low UV cutoff, compatibility with mass spectrometry detection, and lower viscosity. However, its use can also be problematic due to health and environmental concerns. This presentation will highlight how to reduce the use of acetonitrile while maintaining separation performance by using narrower ID columns containing smaller particles. Chromatography using alternatives to acetonitrile such as isopropanol or ethanol will be shown utilizing high-pressure LC instrumentation. Both techniques could be employed when developing more environmentally friendly LC methods.
<blockquote>
Presenter: Bonnie Alden (Principal Scientist, Research &amp; Development, Waters Corporation)
</blockquote>
<blockquote>
Bonnie Alden joined Waters Corporation in 1982 to work with Dr. Patrick McDonald to develop new Sep-Pak Cartridge SPE devices. During her career, she has been a member of teams that brought transformative chromatographic columns to market. These include Symmetry Columns which set the industry standard in reproducibility, 1st hybrid chromatographic packing of XTerra Columns, 2nd generation Ethylene Bridged Hybrid (BEH) and Charged Surface Hybrid (CSH) technologies, as well as the recent development of modern, mixed-mode stationary phases for challenging analyses, such as the retention and separation of polar acids. More than 35 years later, she is still an enthusiastic student of liquid chromatography and separation science. Bonnie is currently a principal scientist in the Small Molecule Portfolio Team where her research interests have focused on developing products to address the needs of scientists in the extensive field of small molecule drug development.
</blockquote>

Waters Corporation: Achieving Your Sustainability Goals with UPLC

Achieving Your Sustainability Goals with UPLC

How to reduce the use of acetonitrile while maintaining separation performance by using narrower ID columns containing smaller particles.

Key Learning Points:
<ul>
<li>Receive an overview of theory of HPLC mobile phase/solid phase and their interactions 
</li>
<li>Learn the differences between mobile phase options, and what to consider when picking a mobile phase 
</li>
<li>Review the of panel results and how mobile phases affected ionization and separation
</li>
</ul>
Who Should Attend:
<ul>
<li>Any HPLC and LC-MS/MS scientists in clinical and toxicology looking to learn more about the theory of HPLC mobile phase</li>
</ul>
<blockquote>
Presenter: Mackenzie Freige (Application Scientist - Clinical, Phenomenex)
</blockquote>
<blockquote>
Mackenzie is an Application Scientist at PhenoLogix, and is based in Torrance, CA. She has undergraduate degrees in Chemistry and in Life Sciences. She joined Phenomenex in 2021, and brings extensive experience in liquid chromatography-mass spectrometry. In her free time she practices yoga and enjoys reading. 
</blockquote>

Phenomenex: HPLC Method Development – Choosing a Mobile Phase for Your Assay

HPLC Method Development – Choosing a Mobile Phase for Your Assay

Receive an overview of theory of HPLC mobile phase/solid phase and their interactions.

HPLC Method Development – Choosing a Mobile Phase

This presentation will provide an overview of analytical quality by design (AQbD) principles and the evolution of QbD in the pharmaceutical development environment.
A brief introduction to the new USP chapter &lt;1220&gt; Analytical Procedures Life Cycle will also be given, including a short case study on stage 1 — procedure design. Additionally, key aspects of the new ICH Q14/Q2(R2) draft guidelines will be discussed along with their implications.
<blockquote>
Presenter: Amanda Guiraldelli, PhD (Scientific Affairs Manager, U.S. Pharmacopeia)
</blockquote>
<blockquote>
Amanda Guiraldelli has been with USP since 2012 and holds the position of scientific affairs manager and principal scientist in the compendial science group-general chapters. She also serves as scientific liaison for the USP Measurement and Data Quality Expert Committee, where she works to develop and revise USP standards related to analytical procedure lifecycle/validation.
</blockquote>
<blockquote>
Previously, Amanda worked as senior scientist at the USP reference standard laboratory for 8 years with characterization of compendial standards. She is visiting professor at the Institute of Chemistry at the University of Campinas (UNICAMP) in Brazil and is a frequent speaker and instructor on topics related to analytical procedure life cycle, analytical quality by design (AQbD) and chromatography. Amanda is a specialist in mass spectrometry, chromatography, omics, and chemometrics and has more than 15 years of experience in pharmaceutical R&amp;D areas.
</blockquote>
<blockquote>
Presenter: Manu Grover (M.S. (Pharm), Business Development Manager, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Manu has more than 21 years of pharmaceutical industry and chromatography experience. He has worked in the fields of manufacturing and analytical research to support IND, NDA, and ANDA filings in pharmaceutical companies like Dr. Reddy&#39;s, Panacea Biotec, and Ozone Pharmaceuticals. In the course of his professional journey, Manu has developed and validated many analytical methods on HPLC, GC, particle sizing, DSC, pXRD, LC/MS, and more. He has successfully filed multiple analytical dossiers in the US and EU markets, filed analytical methods to USP, and handled multiple US FDA audits.
</blockquote>

Agilent Technologies: Introduction to USP 1220 Analytical Procedures Life Cycle and Implications of ICH Q14 and Q2(R2) Guidelines

Introduction to USP 1220 Analytical Procedures Life Cycle and Implications of ICH Q14 and Q2(R2) Guidelines

Analytical quality by design (AQbD) principles and the evolution of QbD in the pharmaceutical development environment.

Introduction to USP 1220 Analytical Procedures Life Cycle

Would you like to know what the new trends in LC are that could help you to achieve better and greener science at the same time?
In this webinar, Dr. Andreas Otto, Agilent Technologies, will discuss how innovation and sustainability go together, and what can be done to reduce the environmental impact of your lab with significant enhancements on scientific outcomes. Topics covered will include columns and supplies selection to reduce run times and its impact on solvent and energy consumption, the different LC techniques from supercritical fluid chromatography, online LC, and a new feed injection sampler that can improve standard LC analysis.
Information about free tools that can make the maximum impact for the minimal change will also be shared.
Key learning objectives
<ul>
<li>Learn how to achieve greener and better LC analysis at the same time
</li>
<li>Discover new LC trends that help you to achieve your goals
</li>
<li>Find out how feed injection mode can help you to perform better chromatography
</li>
<li>Explore the tools that are available so you can start to make a difference immediately
</li>
</ul>
Who should attend?
<ul>
<li>Lab Analysts who have sustainability goals for their lab
</li>
<li>LC users willing to improve their analysis
</li>
<li>Chromatographers who would like to access useful tools
</li>
</ul>
<blockquote>
Presenter: Dr. Andreas Otto (Product Marketing Manager, Liquid Phase Separation Division, Agilent Technologies)
</blockquote>
<blockquote>
Dr. Andreas Otto has worked at Agilent Technologies since May 2018 serving in different roles. In his current position, he leads a technical product marketing team where he coordinates activities for sustainability topics in communication and product development, including third party accreditation of the InfinityLab LC portfolio for the My Green Lab® ACT labels. He is a biochemist by training and has a PhD in Microbiology. Before joining Agilent, he worked with LC and LC/MS for more than 15 years.
</blockquote>
<blockquote>
Presenter: Carrie Haslam (Associate Editor, SelectScience)
</blockquote>
<blockquote>
Dr. Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Materials Science, Alzheimer’s disease and Clinical Diagnostics.
</blockquote>
<blockquote>
Carrie completed a Ph.D. from The University of Plymouth, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.
</blockquote>

SelectScience: Do your objectives to go greener in LC seem difficult to achieve?

Do your objectives to go greener in LC seem difficult to achieve?

How innovation and sustainability go together, and what can be done to reduce the environmental impact of your lab.

Do your objectives to go greener in LC seem difficult?

Oligonucleotide analysis is a critical aspect of molecular biology and therapeutic development, demanding robust and versatile chromatographic techniques for comprehensive characterization.
Several modes of chromatography can be employed to characterize these biomolecules, but when and how to best use each mode can be challenging.
This webinar aims to explore how various chromatographic techniques can be synergistically employed to achieve comprehensive oligonucleotide characterization. Aspects of ion-pair reversed phase chromatography (IP-RPC), hydrophilic interaction liquid chromatography (HILIC), ion exchange chromatography (IEC), and size exclusion chromatography (SEC) will be discussed and how best to employ each mode in oligonucleotide characterization. Several application examples will be utilized to showcase how each of these modes of chromatography can be best utilized to fully resolve and understand the composition of samples containing oligonucleotides.
At the conclusion of the webinar, the audience member will:
<ul>
<li>Understand the strengths and weaknesses of each mode of chromatography in characterizing oligonucleotides.
</li>
<li>Be familiar with key method parameters to adjust when fine-tuning oligonucleotide chromatographic assays
</li>
<li>Gain an appreciation for when to use each mode of chromatography when analyzing oligonucleotides
</li>
</ul>
<blockquote>
Presenter: Cory E. Muraco (Biomolecule Workflows Manager, Merck KGaA, Darmstadt, Germany)
</blockquote>
<blockquote>
Cory joined the company in 2013, starting in the Chemical Standards division, developing and validating analytical methods for testing the purity of certified reference materials using GC and LC methods. In 2022, Cory assumed his present role, where he is tasked with supporting the design, development, and execution of the marketing and R&amp;D strategies around bioanalytical strategy.
</blockquote>
<blockquote>
Presenter: Andrea Krumm (Product Manager, Analytical Columns, Tosoh Bioscience GmbH)
</blockquote>
<blockquote>
Andrea Krumm studied biotechnology before gaining a PhD in Cell and Cancer Biology. After four years as an applications specialist for optical analytical devices used in academic and pharmaceutical research, she joined Tosoh Bioscience GmbH in 2020 as a product manager for analytical columns. Andrea is responsible for gathering customer requirements, application areas and addressing these with new and existing products of the analytical columns line.
</blockquote>

Merck: Exploring Oligonucleotide Diversity: Insights From Multiple Modes of Chromatography

Exploring Oligonucleotide Diversity: Insights From Multiple Modes of Chromatography

How various chromatographic techniques can be synergistically employed to achieve comprehensive oligonucleotide characterization.

LCMS webinars focusing on HPLC - page 31